Filtered By:
Specialty: Drugs & Pharmacology
Infectious Disease: Outbreaks
This page shows you your search results in order of date.
Order by Relevance | Date
Total 529 results found since Jan 2013.
Independent risk factors for COVID-19-associated coagulopathy
CONCLUSIONS: Not receiving LMWH, high levels of D-dimer, initial LDH, and initial ferritin are independent risk factors for CAC. DIC does not appear to develop based on COVID-19.PMID:37667962 | DOI:10.26355/eurrev_202308_33440
Source: Pharmacological Reviews - September 5, 2023 Category: Drugs & Pharmacology Authors: Y B Tor M Ozbalak S Kalayoglu-Besisik E Aksoy A A Cagatay A Gul M Erelel N Senkal A Medetalibeyoglu M Kose T Tukek Source Type: research
Telogen effluvium and COVID-19: a cross-sectional study
CONCLUSIONS: In our study, the incidence of TE was highly related to COVID-19 infections among both sexes. However, the incidence was greater among the female population. The awareness level toward post-COVID-19 TE was poor among most of the participants in our study.PMID:37667959 | DOI:10.26355/eurrev_202308_33437
Source: Pharmacological Reviews - September 5, 2023 Category: Drugs & Pharmacology Authors: A Aldahish R Vasudevan H Salem A Alqahtani S AlQasim A Alqhatani M Al Shahrani L Al Mohsen M Hajla D Calina J Sharifi-Rad Source Type: research
Independent risk factors for COVID-19-associated coagulopathy
CONCLUSIONS: Not receiving LMWH, high levels of D-dimer, initial LDH, and initial ferritin are independent risk factors for CAC. DIC does not appear to develop based on COVID-19.PMID:37667962 | DOI:10.26355/eurrev_202308_33440
Source: Pharmacological Reviews - September 5, 2023 Category: Drugs & Pharmacology Authors: Y B Tor M Ozbalak S Kalayoglu-Besisik E Aksoy A A Cagatay A Gul M Erelel N Senkal A Medetalibeyoglu M Kose T Tukek Source Type: research
Telogen effluvium and COVID-19: a cross-sectional study
CONCLUSIONS: In our study, the incidence of TE was highly related to COVID-19 infections among both sexes. However, the incidence was greater among the female population. The awareness level toward post-COVID-19 TE was poor among most of the participants in our study.PMID:37667959 | DOI:10.26355/eurrev_202308_33437
Source: Pharmacological Reviews - September 5, 2023 Category: Drugs & Pharmacology Authors: A Aldahish R Vasudevan H Salem A Alqahtani S AlQasim A Alqhatani M Al Shahrani L Al Mohsen M Hajla D Calina J Sharifi-Rad Source Type: research
Role of cancer-educated mesenchymal stromal cells on tumor progression
Biomed Pharmacother. 2023 Sep 1;166:115405. doi: 10.1016/j.biopha.2023.115405. Online ahead of print.ABSTRACTThe malignant tumor is the main cause of human deaths worldwide. Current therapies focusing on the tumor itself have achieved unprecedented benefits. Various pro-tumorigenic factors in the tumor microenvironment (TME) could abolish the effect of cancer therapy. Mesenchymal stromal cells (MSCs) are one of the substantial components in the tumor microenvironment, contributing to tumor progression. However, MSCs are not inherently tumor-promoting. Indeed, they acquire pro-tumorigenic properties under the education of t...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - September 3, 2023 Category: Drugs & Pharmacology Authors: Ting Liu Shuwei Guo Yong Ji Wei Zhu Source Type: research
Mycotoxins and Amyotrophic Lateral Sclerosis: food exposure, nutritional implications and dietary solutions
In conclusion, after suggesting some possible solutions to mitigate mycotoxin exposure risk, we affirm that future collaborations between scientists and policymakers are important to develop sustainable interventions and promote health through dietary diversity.PMID:37592793 | DOI:10.2174/1871527323666230817145434
Source: CNS and Neurological Disorders Drug Targets - August 18, 2023 Category: Drugs & Pharmacology Authors: Umberto Manera Enrico Matteoni Antonio Canosa Stefano Callegaro Federico Casale Daniela Marchis Rosario Vasta Cristina Moglia Adriano Chi ò Andrea Calvo Source Type: research
Emerging pharmacological strategies for treating and preventing mpox
Expert Rev Clin Pharmacol. 2023 Aug 17. doi: 10.1080/17512433.2023.2249820. Online ahead of print.ABSTRACTINTRODUCTION: Since May 2022, there have been nearly 87,000 documented cases of mpox worldwide, with 119 deaths. Pharmacological interventions for mpox include the MVA-BN smallpox vaccine, tecovirimat, cidofovir or its pro-drug brincidofovir, and vaccinia immune globulin intravenous (VIGIV).AREAS COVERED: The literature search and information gathering for this review included the PubMed database focusing on mpox and monkeypox, in combination with tecovirimat, brincidofovir, cidofovir, VIGIV, and smallpox vaccine. WHO....
Source: Expert Review of Clinical Pharmacology - August 18, 2023 Category: Drugs & Pharmacology Authors: Douglas W Grosenbach Andrew T Russo Emily D Blum Dennis E Hruby Source Type: research
United States' regulatory approved pharmacotherapies for nuclear reactor explosions and anthrax-associated bioterrorism
Expert Opin Drug Saf. 2023 Aug 18:1-6. doi: 10.1080/14740338.2023.2245748. Online ahead of print.ABSTRACTINTRODUCTION: Nuclear reactor incidents and bioterrorism outbreaks are concerning public health disasters. Little is known about US Food and Drug Administration (FDA)-approved agents that can mitigate consequences of these events. We review FDA data supporting regulatory approvals of these agents.AREAS COVERED: We reviewed pharmaceutical products approved to treat Hematopoietic Acute Radiation Syndrome (H-ARS) and to treat or prevent pulmonary infections following Bacillus anthracis (anthrax) exposure. Four drugs were a...
Source: Expert Opinion on Drug Safety - August 18, 2023 Category: Drugs & Pharmacology Authors: Charles L Bennett Peter Georgantopoulos Robert Peter Gale Kevin Knopf William J Hrushesky Chadi Nabhan James O Armitage Source Type: research
Mycotoxins and Amyotrophic Lateral Sclerosis: food exposure, nutritional implications and dietary solutions
In conclusion, after suggesting some possible solutions to mitigate mycotoxin exposure risk, we affirm that future collaborations between scientists and policymakers are important to develop sustainable interventions and promote health through dietary diversity.PMID:37592793 | DOI:10.2174/1871527323666230817145434
Source: CNS and Neurological Disorders Drug Targets - August 18, 2023 Category: Drugs & Pharmacology Authors: Umberto Manera Enrico Matteoni Antonio Canosa Stefano Callegaro Federico Casale Daniela Marchis Rosario Vasta Cristina Moglia Adriano Chi ò Andrea Calvo Source Type: research
Emerging pharmacological strategies for treating and preventing mpox
Expert Rev Clin Pharmacol. 2023 Aug 17. doi: 10.1080/17512433.2023.2249820. Online ahead of print.ABSTRACTINTRODUCTION: Since May 2022, there have been nearly 87,000 documented cases of mpox worldwide, with 119 deaths. Pharmacological interventions for mpox include the MVA-BN smallpox vaccine, tecovirimat, cidofovir or its pro-drug brincidofovir, and vaccinia immune globulin intravenous (VIGIV).AREAS COVERED: The literature search and information gathering for this review included the PubMed database focusing on mpox and monkeypox, in combination with tecovirimat, brincidofovir, cidofovir, VIGIV, and smallpox vaccine. WHO....
Source: Pharmacological Reviews - August 18, 2023 Category: Drugs & Pharmacology Authors: Douglas W Grosenbach Andrew T Russo Emily D Blum Dennis E Hruby Source Type: research
